Finanzen von Krystal Biotech Inc (KRYS)KRYSKrystal Biotech Inc

Evaluating the bottom line, Krystal Biotech, Inc. maintains a gross margin of 94.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 49.00%, while the net margin is 45.94%. These profitability ratios, combined with a Return on Equity (ROE) of 20.12%, provide a clear picture of how effectively KRYS converts its operational activities into shareholder value.

In the context of the broader market, KRYS competes directly with industry leaders such as AXSM and APGE. With a market capitalization of $10.40B, it holds a significant position in the sector. When comparing efficiency, KRYS's gross margin of 94.60% stands against AXSM's 93.06% and APGE's N/A. Such benchmarking helps identify whether Krystal Biotech, Inc. is trading at a premium or discount relative to its financial performance.

Krystal Biotech has shown consistent revenue growth, with total revenue increasing from $83.84 million in Q3 2024 to $119.22 million in Q2 2026. The net income for Q2 2026 was $54.77 million, reflecting strong profitability.